Calibrated automated thrombin generation measurement in clotting plasma

H. Coenraad Hemker*, Peter Giesen, Raed Al Dieri, Veronique Regnault, Eric de Smedt, Rob Wagenvoord, Thomas Lecompte, Suzette Beguin

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    1 Downloads (Pure)

    Abstract

    Calibrated automated thrombography displays the concentration of thrombin in clotting plasma with or without platelets (platelet-rich plasma/platelet-poor plasma, PRP/PPP) in up to 48 samples by monitoring the splitting of a fluorogenic substrate and comparing it to a constant known thrombin activity in a parallel, non-clotting sample. Thus, the non-linearity of the reaction rate with thrombin concentration is compensated for, and adding an excess of substrate can be avoided. Standard conditions were established at which acceptable experimental variation accompanies sensitivity to pathological changes. The coefficients of variation of the surface under the curve (endogenous thrombin potential) are: within experiment similar to3%; intra-individual: <5% in PPP, <8% in PRP; interindividual 15% in PPP and 19% in PRP. In PPP, calibrated automated thrombography shows all clotting factor deficiencies (except factor XIII) and the effect of all anticoagulants [AVK, heparin(-likes), direct inhibitors]. In PRP, it is diminished in von Willebrand's disease, but it also shows the effect of platelet inhibitors (e.g. aspirin and abciximab). Addition of activated protein C (APC) or thrombomodulin inhibits thrombin generation and reflects disorders of the APC system (congenital and acquired resistance, deficiencies and lupus antibodies) independent of concomitant inhibition of the procoagulant pathway as for example by anticoagulants. Copyright (C) 2003 S. Karger AG, Basel.
    Original languageEnglish
    Pages (from-to)4-15
    Number of pages12
    JournalPathophysiology of Haemostasis and Thrombosis
    Volume33
    Issue number1
    DOIs
    Publication statusPublished - 2003

    Cite this